174 related articles for article (PubMed ID: 25110436)
1. RAD51 potentiates synergistic effects of chemotherapy with PCI-24781 and cis-diamminedichloroplatinum on gastric cancer.
He WL; Li YH; Hou WJ; Ke ZF; Chen XL; Lu LY; Cai SR; Song W; Zhang CH; He YL
World J Gastroenterol; 2014 Aug; 20(29):10094-107. PubMed ID: 25110436
[TBL] [Abstract][Full Text] [Related]
2. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma.
Lopez G; Liu J; Ren W; Wei W; Wang S; Lahat G; Zhu QS; Bornmann WG; McConkey DJ; Pollock RE; Lev DC
Clin Cancer Res; 2009 May; 15(10):3472-83. PubMed ID: 19417021
[TBL] [Abstract][Full Text] [Related]
3. Treatment of nasopharyngeal carcinoma cells with the histone-deacetylase inhibitor abexinostat: cooperative effects with cis-platin and radiotherapy on patient-derived xenografts.
Gressette M; Vérillaud B; Jimenez-Pailhès AS; Lelièvre H; Lo KW; Ferrand FR; Gattolliat CH; Jacquet-Bescond A; Kraus-Berthier L; Depil S; Busson P
PLoS One; 2014; 9(3):e91325. PubMed ID: 24618637
[TBL] [Abstract][Full Text] [Related]
4. Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
Nidhyanandan S; Thippeswamy BS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Karthikeyan K; Khan FR; Raghul J; Vijaykanth G; Narayanan S
Anticancer Drugs; 2017 Oct; 28(9):1002-1017. PubMed ID: 28727579
[TBL] [Abstract][Full Text] [Related]
5. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination.
Adimoolam S; Sirisawad M; Chen J; Thiemann P; Ford JM; Buggy JJ
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19482-7. PubMed ID: 18042714
[TBL] [Abstract][Full Text] [Related]
6. ERK inhibition enhances TSA-induced gastric cancer cell apoptosis via NF-κB-dependent and Notch-independent mechanism.
Yao J; Qian CJ; Ye B; Zhang X; Liang Y
Life Sci; 2012 Sep; 91(5-6):186-93. PubMed ID: 22781708
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
Zhao J; Xie C; Edwards H; Wang G; Taub JW; Ge Y
Oncotarget; 2017 Jan; 8(4):6319-6329. PubMed ID: 28030834
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells.
Yang C; Choy E; Hornicek FJ; Wood KB; Schwab JH; Liu X; Mankin H; Duan Z
Cancer Chemother Pharmacol; 2011 Feb; 67(2):439-46. PubMed ID: 20461381
[TBL] [Abstract][Full Text] [Related]
9. Additive Interaction of Cisplatin and Histone Deacetylase Inhibitors Combined Treatment in Rhabdomyosarcoma Cells - An Isobolographic Analysis.
Jarząb A; Łuszczki JJ; Guz M; Gumbarewicz E; Polberg K; Stepulak A
Anticancer Res; 2017 Mar; 37(3):1067-1074. PubMed ID: 28314266
[TBL] [Abstract][Full Text] [Related]
10. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin.
Ito M; Yamamoto S; Nimura K; Hiraoka K; Tamai K; Kaneda Y
J Gene Med; 2005 Aug; 7(8):1044-52. PubMed ID: 15756713
[TBL] [Abstract][Full Text] [Related]
11. Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.
Morelli MP; Tentler JJ; Kulikowski GN; Tan AC; Bradshaw-Pierce EL; Pitts TM; Brown AM; Nallapareddy S; Arcaroli JJ; Serkova NJ; Hidalgo M; Ciardiello F; Eckhardt SG
Clin Cancer Res; 2012 Feb; 18(4):1051-62. PubMed ID: 22173548
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer.
Murakami K; Kita Y; Sakatani T; Hamada A; Mizuno K; Nakamura K; Takada H; Matsumoto K; Sano T; Goto T; Akamatsu S; Saito R; Tsuruyama T; Ogawa O; Kobayashi T
Cancer Sci; 2021 Sep; 112(9):3669-3681. PubMed ID: 34212455
[TBL] [Abstract][Full Text] [Related]
13. Ceritinib increases sensitivity of AKT inhibitors to gastric cancer.
Wang J; Xu X; Wang T; Guo Q; Dai X; Guo H; Zhang W; Cheng S; Chen X; Ding L
Eur J Pharmacol; 2021 Apr; 896():173879. PubMed ID: 33515539
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
Xie X; He G; Siddik ZH
Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
[TBL] [Abstract][Full Text] [Related]
15. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
16. Low-dose all-trans retinoic acid enhances cytotoxicity of cisplatin and 5-fluorouracil on CD44(+) cancer stem cells.
Najafzadeh N; Mazani M; Abbasi A; Farassati F; Amani M
Biomed Pharmacother; 2015 Aug; 74():243-51. PubMed ID: 26349992
[TBL] [Abstract][Full Text] [Related]
17. Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells.
Chang H; Rha SY; Jeung HC; Jung JJ; Kim TS; Kwon HJ; Kim BS; Chung HC
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1901-13. PubMed ID: 20217129
[TBL] [Abstract][Full Text] [Related]
18. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.
Jaeger-Lansky A; Cejka D; Ying L; Preusser M; Hoeflmayer D; Fuereder T; Koehrer S; Wacheck V
Cancer Biol Ther; 2010 Jun; 9(11):919-27. PubMed ID: 20404549
[TBL] [Abstract][Full Text] [Related]
19. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
Rahmani M; Aust MM; Benson EC; Wallace L; Friedberg J; Grant S
Clin Cancer Res; 2014 Sep; 20(18):4849-60. PubMed ID: 25070836
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.
Krumm A; Barckhausen C; Kücük P; Tomaszowski KH; Loquai C; Fahrer J; Krämer OH; Kaina B; Roos WP
Cancer Res; 2016 May; 76(10):3067-77. PubMed ID: 26980768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
